Immunome Inc (IMNM)

Currency in USD
24.01
-0.38(-1.56%)
Closed·
24.010.00(0.00%)
·
IMNM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
23.6624.87
52 wk Range
7.9627.65
Key Statistics
Prev. Close
24.39
Open
24.17
Day's Range
23.66-24.87
52 wk Range
7.96-27.65
Volume
2.19M
Average Volume (3m)
1.31M
1-Year Change
170.0787%
Book Value / Share
5.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMNM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
35.77
Upside
+48.98%
Members' Sentiments
Bearish
Bullish
ProTips
10 analysts have revised their earnings upwards for the upcoming period

Immunome Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Analyst Ratings

13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 35.77
(+48.98% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Truist Securities
Buy37.00+54.10%36.00Maintain28-05-2026
Barclays
Buy36.00+49.94%-New Coverage28-05-2026
Lake Street
Buy30.00+24.95%32.00Maintain05-03-2026
Craig-Hallum
Buy36.00+49.94%33.00Maintain04-03-2026
Stephens
Buy30.00+24.95%33.00Maintain04-03-2026

Earnings

Latest Release
12-05-2026
EPS / Forecast
-0.48 / -0.55
Revenue / Forecast
-- / 200K
EPS Revisions
Last 90 days

IMNM Income Statement

Compare IMNM to Peers and Sector

Metrics to compare
IMNM
Peers
Sector
Relationship
P/E Ratio
−12.1x−5.0x−0.4x
PEG Ratio
−0.48−0.440.00
Price/Book
4.6x2.5x2.6x
Price / LTM Sales
677.2x27.4x3.0x
Upside (Analyst Target)
49.9%47.9%51.9%
Fair Value Upside
Unlock−6.7%9.4%Unlock

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
58.38M51.55%1.40B
Other Institutional Investors
81.02M48.45%1.94B
Public Companies & Retail Investors
0.000.00%0.00
Total
139.4M100.00%3.33B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
T. Rowe Price Group, Inc.16.97%1,92,22,8744,59,427
FMR LLC14.98%1,69,69,9544,05,582

FAQ

What Is the Immunome (IMNM) Share Price Today?

The Immunome share price today is 24.01.

What is the current Immunome (IMNM) share price and day range?

As of 09-07-2026, the Immunome share price is 24.01, with a previous close of 24.39. The share price has ranged from 23.66 to 24.87 today, while the 52-week range spans from 7.96 to 27.65.

What Is the Immunome Market Cap?

As of today, Immunome market cap is 2.72B.

What Is the Immunome (IMNM) Share Price Target?

The average 12-month share price target for Immunome is 35.77, with a high estimate of 40 and a low estimate of 30. 13 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +48.98% Upside potential.

What Is Immunome's Earnings Per Share (TTM)?

The Immunome EPS (TTM) is -2.34.

When Is the Next Immunome Earnings Date?

Immunome will release its next earnings report on 19-08-2026.

From a Technical Analysis Perspective, Is IMNM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Immunome Trade On?

Immunome is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Immunome?

The stock symbol for Immunome is "IMNM."

How Many Times Has Immunome Stock Split?

Immunome has split 0 times.

How Many Employees Does Immunome Have?

Immunome has 206 employees.

What Is the IMNM Premarket Price?

IMNM's last pre-market stock price is 24.04. The pre-market share volume is 4,450.00, and the stock has changed by -0.35, or -1.44%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.